PRECIGEN, INC. Cash and Cash Equivalents, Period Increase (Decrease)
PRECIGEN, INC. (PGEN) reported Cash and Cash Equivalents, Period Increase (Decrease) of $5.50 million for the 12-month period ending 2017-12-31, per its 10-K filed 2018-03-01.
Discontinued › Cash Flow › Change in Cash
us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease · last filed 2018-03-01
- PRECIGEN, INC. cash and cash equivalents, period increase (decrease) for the quarter ending 2017-12-31 was $3.90M.
- PRECIGEN, INC. cash and cash equivalents, period increase (decrease) for the quarter ending 2017-09-30 was -$144.00K.
- PRECIGEN, INC. cash and cash equivalents, period increase (decrease) for the quarter ending 2017-06-30 was -$5.49M, a 158.75% decline year-over-year.
- PRECIGEN, INC. cash and cash equivalents, period increase (decrease) for the quarter ending 2017-03-31 was $7.25M, a 27.19% decline year-over-year.
- PRECIGEN, INC. cash and cash equivalents, period increase (decrease) for fiscal 2017 was $5.50M.
- PRECIGEN, INC. cash and cash equivalents, period increase (decrease) for fiscal 2016 was -$73.17M, a 167.56% decline from fiscal 2015.
- PRECIGEN, INC. cash and cash equivalents, period increase (decrease) for fiscal 2015 was $108.32M.
- PRECIGEN, INC. cash and cash equivalents, period increase (decrease) for fiscal 2014 was -$22.04M, a 156.37% decline from fiscal 2013.
| Period end | Cash and Cash Equivalents, Period Increase (Decrease) 3 month | Cash and Cash Equivalents, Period Increase (Decrease) 6 month | Cash and Cash Equivalents, Period Increase (Decrease) 9 month | Cash and Cash Equivalents, Period Increase (Decrease) 12 month |
|---|---|---|---|---|
| 2017-12-31 | $3.90M derived: 10-K 12 month − 10-Q 9 month · filed 2018-03-01 | $3.75M derived: sum of 2 quarters · filed 2018-03-01 | -$1.74M derived: sum of 3 quarters · filed 2018-03-01 | $5.50M 10-K · filed 2018-03-01 |
| 2017-09-30 | -$144.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2017-11-09 | -$5.64M derived: sum of 2 quarters · filed 2017-11-09 | $1.61M 10-Q · filed 2017-11-09 | -$5.49M derived: sum of 4 quarters · filed 2018-03-01 |
| 2017-06-30 | -$5.49M derived: 10-Q 6 month − 10-Q 3 month · filed 2017-08-09 | $1.75M 10-Q · filed 2017-08-09 | -$5.35M derived: sum of 3 quarters · filed 2018-03-01 | -$90.72M derived: sum of 4 quarters · filed 2018-03-01 |
| 2017-03-31 | $7.25M 10-Q · filed 2017-05-10 | $145.00K derived: sum of 2 quarters · filed 2018-03-01 | -$85.23M derived: sum of 3 quarters · filed 2018-03-01 | -$75.88M derived: sum of 4 quarters · filed 2018-03-01 |
| 2016-12-31 | -$7.10M derived: 10-K 12 month − 10-Q 9 month · filed 2018-03-01 | -$92.47M derived: sum of 2 quarters · filed 2018-03-01 | -$83.13M derived: sum of 3 quarters · filed 2018-03-01 | -$73.17M 10-K · filed 2018-03-01 |
| 2016-09-30 | -$85.37M derived: 10-Q 9 month − 10-Q 6 month · filed 2017-11-09 | -$76.03M derived: sum of 2 quarters · filed 2017-11-09 | -$66.08M 10-Q · filed 2017-11-09 | -$55.73M derived: sum of 4 quarters · filed 2018-03-01 |
| 2016-06-30 | $9.35M derived: 10-Q 6 month − 10-Q 3 month · filed 2017-08-09 | $19.30M 10-Q · filed 2017-08-09 | $29.65M derived: sum of 3 quarters · filed 2018-03-01 | $56.18M derived: sum of 4 quarters · filed 2018-03-01 |
| 2016-03-31 | $9.95M 10-Q · filed 2017-05-10 | $20.30M derived: sum of 2 quarters · filed 2018-03-01 | $46.83M derived: sum of 3 quarters · filed 2018-03-01 | $46.72M derived: sum of 4 quarters · filed 2018-03-01 |
| 2015-12-31 | $10.35M derived: 10-K 12 month − 10-Q 9 month · filed 2018-03-01 | $36.88M derived: sum of 2 quarters · filed 2018-03-01 | $36.77M derived: sum of 3 quarters · filed 2018-03-01 | $108.32M 10-K · filed 2018-03-01 |
| 2015-09-30 | $26.53M derived: 10-Q 9 month − 10-Q 6 month · filed 2016-11-09 | $26.42M derived: sum of 2 quarters · filed 2016-11-09 | $97.97M 10-Q · filed 2016-11-09 | $100.73M derived: sum of 4 quarters · filed 2017-03-01 |
| 2015-06-30 | -$116.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2016-08-09 | $71.43M 10-Q · filed 2016-08-09 | $74.19M derived: sum of 3 quarters · filed 2017-03-01 | $24.39M derived: sum of 4 quarters · filed 2017-03-01 |
| 2015-03-31 | $71.55M 10-Q · filed 2016-05-10 | $74.31M derived: sum of 2 quarters · filed 2017-03-01 | $24.51M derived: sum of 3 quarters · filed 2017-03-01 | -$11.04M derived: sum of 4 quarters · filed 2017-03-01 |
| 2014-12-31 | $2.76M derived: 10-K 12 month − 10-Q 9 month · filed 2017-03-01 | -$47.04M derived: sum of 2 quarters · filed 2017-03-01 | -$82.59M derived: sum of 3 quarters · filed 2017-03-01 | -$22.04M 10-K · filed 2017-03-01 |
| 2014-09-30 | -$49.80M derived: 10-Q 9 month − 10-Q 6 month · filed 2015-11-09 | -$85.35M derived: sum of 2 quarters · filed 2015-11-09 | -$24.80M 10-Q · filed 2015-11-09 | -$36.52M derived: sum of 4 quarters · filed 2016-02-29 |
| 2014-06-30 | -$35.55M derived: 10-Q 6 month − 10-Q 3 month · filed 2015-08-10 | $25.00M 10-Q · filed 2015-08-10 | $13.28M derived: sum of 3 quarters · filed 2016-02-29 | $40.04M derived: sum of 4 quarters · filed 2016-02-29 |
| 2014-03-31 | $60.54M 10-Q · filed 2015-05-11 | $48.83M derived: sum of 2 quarters · filed 2016-02-29 | $75.59M derived: sum of 3 quarters · filed 2016-02-29 | $50.33M derived: sum of 4 quarters · filed 2016-02-29 |
| 2013-12-31 | -$11.71M derived: 10-K 12 month − 10-Q 9 month · filed 2016-02-29 | $15.05M derived: sum of 2 quarters · filed 2016-02-29 | -$10.21M derived: sum of 3 quarters · filed 2016-02-29 | $39.11M 10-K · filed 2016-02-29 |
| 2013-09-30 | $26.76M derived: 10-Q 9 month − 10-Q 6 month · filed 2014-11-13 | $1.50M derived: sum of 2 quarters · filed 2014-11-13 | $50.82M 10-Q · filed 2014-11-13 | $57.14M derived: sum of 4 quarters · filed 2015-03-02 |
| 2013-06-30 | -$25.26M derived: 10-Q 6 month − 10-Q 3 month · filed 2014-08-14 | $24.06M 10-Q · filed 2014-08-14 | $30.38M derived: sum of 3 quarters · filed 2015-03-02 | $15.13M derived: sum of 4 quarters · filed 2015-03-02 |
| 2013-03-31 | $49.32M 10-Q · filed 2014-05-09 | $55.64M derived: sum of 2 quarters · filed 2015-03-02 | $40.39M derived: sum of 3 quarters · filed 2015-03-02 | |
| 2012-12-31 | $6.32M derived: 10-K 12 month − 10-Q 9 month · filed 2015-03-02 | -$8.93M derived: sum of 2 quarters · filed 2015-03-02 | -$9.22M 10-K · filed 2015-03-02 | |
| 2012-09-30 | -$15.25M derived: 10-Q 9 month − 10-Q/A 6 month · filed 2013-11-07 | -$15.55M 10-Q · filed 2013-11-07 | ||
| 2012-06-30 | -$297.00K 10-Q/A · filed 2013-10-21 | |||
| 2011-12-31 | $2.26M 10-K · filed 2014-03-31 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| NewAmsterdam Pharma Co N.V. (NAMS) | $2.719B | -15.37 | |
| MBX Biosciences, Inc. (MBX) | United States | $2.664B | -25.36 |
| Disc Medicine, Inc. (IRON) | United States | $2.553B | -11.40 |
| Immunome Inc. (IMNM) | United States | $2.538B | -9.45 |
| SUPERNUS PHARMACEUTICALS, INC. (SUPN) | United States | $2.517B | -24.63 |
| Nurix Therapeutics, Inc. (NRIX) | United States | $2.457B | -5.39 |
| Dyne Therapeutics, Inc. (DYN) | United States | $3.084B | -7.09 |
| SELLAS Life Sciences Group, Inc. (SLS) | United States | $2.420B | -91.87 |
| uniQure N.V. (QURE) | $2.416B | -4.93 | |
| Vera Therapeutics, Inc. (VERA) | United States | $2.402B | -7.67 |